|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
DAR AL-DAWA DEVP. & INV.CO.
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B; D , 3rd trimester
|
|
INDICATIONS:
|
|
Arthritis, osteoarthritis |
|
Arthritis, rheumatoid |
|
Dysmenorrhea |
|
Fever |
|
Pain, mild to moderate |
| |
|
|
SIDE EFFECTS:
|
|
thrombocytopenia |
|
tinnitus |
|
toxic epidermal necrolysis |
|
urticaria |
|
visual impairment |
|
wheezing |
|
abdominal pain |
|
agranulocytosis |
|
anemia |
|
anorexia |
|
aplastic anemia |
|
aseptic meningitis |
|
azotemia |
|
bleeding |
|
bronchospasm |
|
bullous rash |
|
confusion |
|
constipation |
|
diarrhea |
|
dizziness |
|
drowsiness |
|
dyspepsia |
|
dysphagia |
|
dyspnea |
|
edema |
|
elevated hepatic enzymes |
|
erythema multiforme |
|
esophageal stricture |
|
esophageal ulceration |
|
esophagitis |
|
flatulence |
|
gastritis |
|
GI bleeding |
|
GI perforation |
|
headache |
|
heart failure |
|
hematuria |
|
hemolytic anemia |
|
hepatitis |
|
hyperkalemia |
|
hypertension |
|
hyperuricemia |
|
interstitial nephritis |
|
jaundice |
|
maculopapular rash |
|
nausea/vomiting |
|
nephrotic syndrome |
|
neutropenia |
|
odynophagia |
|
pancreatitis |
|
pancytopenia |
|
peptic ulcer |
|
peripheral edema |
|
photophobia |
|
platelet dysfunction |
|
proteinuria |
|
pruritus |
|
pseudotumor cerebri |
|
pyrosis (heartburn) |
|
rash (unspecified) |
|
renal failure (unspecified) |
|
renal papillary necrosis |
|
Stevens-Johnson syndrome |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
acute bronchospasm |
|
alcoholism |
|
anemia |
|
anticoagulant therapy |
|
asthma |
|
bone marrow suppression |
|
breast-feeding |
|
chemotherapy |
|
coagulopathy |
|
corticosteroid therapy |
|
dental disease |
|
dental work |
|
diabetes mellitus |
|
edema |
|
elderly |
|
GI bleeding |
|
GI disease |
|
heart failure |
|
hematological disease |
|
hemophilia |
|
hepatic disease |
|
hypertension |
|
immunosuppression |
|
intramuscular injections |
|
jaundice |
|
labor |
|
nasal polyps |
|
neutropenia |
|
peptic ulcer disease |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
rheumatoid arthritis |
|
surgery |
|
systemic lupus erythematosus (SLE) |
|
thrombocytopenia |
|
tobacco smoking |
|
ulcerative colitis |
|
urticaria |
|
|
ADULT DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Oral, 1200 to 3200 mg a day in three or four divided doses. After a satisfactory response has been obtained, dosage should be reduced to the lowest maintenance dose that provides continuing control of symptoms.
Note: Higher doses generally are required in rheumatoid arthritis than in osteoarthritis.
Analgesic (mild to moderate pain)
Antipyretic or
Antidysmenorrheal-Oral, 200 to 400 mg every four to six hours as needed. |
|
MAXIMUM ADULT DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Up to 3600 mg per day. The maximum dosage should be used only if the clinical benefit is increased sufficiently to offset the higher risk of adverse effects.
Analgesic
Antipyretic; or
Antidysmenorrheal-For patient self-medication (over-the-counter use): Not to exceed 1200 mg per day. |
|
PEDIATRIC DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Infants up to 6 months of age: Safety and efficacy have not been established.
Children 6 months to 12 years of age: Oral, initially 30 to 40 mg per kg of body weight a day in three or four divided doses, although 20 mg per kg of body weight per day may be sufficient for patients with mild disease. After a satisfactory response has been achieved, dosage should be reduced to the lowest dose needed to control disease activity.
Antipyretic-Infants up to 6 months of age: Safety and efficacy have not been established.
Children 6 months to 12 years of age: Oral, 5 mg per kg of body weight for fevers less than 39.17 °C (102.5 °F) and 10 mg per kg of body weight for higher fevers. Dosage may be repeated, if necessary, at intervals of 4 to 6 hours or more. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
Antirheumatic-Oral, 50 mg per kg of body weight per day.
Antipyretic-Oral, 40 mg per kg of body weight per day. |
|
ELDERLY DOSE:
|
|
|
|
|
|
|